Notable Labs (NTBLQ) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36581
Entity Registrant Name	Notable Labs, Ltd.
Entity Central Index Key	0001603207
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	320 Hatch Drive
Entity Address, City or Town	Foster City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94404
City Area Code	(415)
Local Phone Number	851-2410
Title of 12(b) Security	Ordinary Shares, par value NIS 0.35 per share
Trading Symbol	NTBL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,018,261

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,171	$ 11,825
Prepaid expenses and other current assets	3,544	3,645
Total current assets	11,715	15,470
Property and equipment, net	279	316
Finance lease right-of-use assets, net	317	337
Operating lease right-of-use assets	1,581	1,694
Investment in SAFE	1,500	1,500
Other assets	206	224
Total assets	15,598	19,541
Current liabilities:
Accounts payable	1,522	1,755
Accrued expenses and other current liabilities	434	418
Accounts payable and accrued expenses - related parties	22	42
Finance lease liabilities, current	79	78
Operating lease liabilities, current	456	445
Total current liabilities	2,513	2,738
Finance lease liabilities, net of current amount	243	263
Operating lease liabilities, net of current amount	1,145	1,263
Warrant liability	152	163
Total liabilities	4,053	4,427
Commitments and contingencies
Shareholders’ equity
Ordinary shares, NIS 0.35 par value, 34,285,714 shares authorized as of March 31, 2024 and December 31, 2023 and 9,018,261 issued and outstanding as of March 31, 2024 and December 31, 2023	788	788
Additional paid-in capital	96,656	96,524
Accumulated deficit	(86,074)	(82,308)
Accumulated other comprehensive income	175	110
Total shareholders’ equity	11,545	15,114
Total liabilities and shareholders’ equity	$ 15,598	$ 19,541

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - ₪ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	₪ 0.35	₪ 0.35
Common stock, shares authorized	34,285,714	34,285,714
Common stock, shares issued	9,018,261	9,018,261
Common stock, shares outstanding	9,018,261	9,018,261

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Services revenue	$ 1
Cost of services
Gross profit	1
Operating expenses
Research and development	1,550	1,596
General and administrative	2,289	3,923
Total operating expenses	3,839	5,519
Loss from operations	(3,838)	(5,519)
Other income (expense), net
Change in fair value of SAFEs		(1,865)
Change in fair value of warrant liability	11	1,096
Other income	61	16
Total Other income (expense)	72	(753)
Net loss	(3,766)	(6,272)
Other comprehensive income
Change in foreign currency translation adjustment	65
Comprehensive loss	$ (3,701)	$ (6,272)
Net loss per share basic	$ (0.42)	$ (6.46)
Net loss per share diluted	$ (0.42)	$ (6.46)
Weighted-average common shares outstanding basic	9,018,261	970,192
Weighted-average common shares outstanding diluted	9,018,261	970,192

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Redeemable Convertible Preferred Stock [Member]	Ordinary Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Temporary equity, balance, shares at Dec. 31, 2022	464,321
Temporary equity, balance at Dec. 31, 2022	$ 35,352
Balance at Dec. 31, 2022	35,352		$ 15	$ 34,061	$ (71,044)		$ (36,968)
Balance, shares at Dec. 31, 2022			970,192
Share-based compensation expense				116			116
Net loss					(6,272)		(6,272)
Net loss							(6,272)
Temporary equity, balance, shares at Mar. 31, 2023	464,321
Temporary equity, balance at Mar. 31, 2023	$ 35,352
Ending balance, value at Mar. 31, 2023	$ 35,352		$ 15	34,177	(77,316)		(43,124)
Balance, shares at Mar. 31, 2023			970,192
Balance at Dec. 31, 2023		$ 788		96,524	(82,308)	110	15,114
Balance, shares at Dec. 31, 2023		9,018,261
Share-based compensation expense				132			132
Net loss					(3,766)	65	(3,701)
Net loss							(3,766)
Ending balance, value at Mar. 31, 2024		$ 788		$ 96,656	$ (86,074)	$ 175	$ 11,545
Balance, shares at Mar. 31, 2024		9,018,261

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,766)	$ (6,272)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	63	68
Share-based compensation	132	116
Non-cash operating leases	113	184
Change in fair value of SAFEs		1,865
Change in fair value of warrant liability	(11)	(1,096)
Change in operating assets and liabilities
Prepaid expenses	237	577
Other assets	18
Accounts payable	(230)	1,735
Accrued expenses and other current liabilities	10	87
Accounts payable - related parties	(20)
Operating lease liabilities	(107)	(187)
Net cash used in operating activities	(3,561)	(2,923)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(6)	(4)
Net cash used in investing activities	(6)	(4)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of finance lease liabilities	(19)	(7)
Proceeds from issuance of SAFE agreements		4,351
Net cash (used in) provided by financing activities	(19)	4,344
Net increase (decrease) in cash and cash equivalents	(3,586)	1,417
Effect of exchange rate changes on cash	(68)
Cash and cash equivalents at the beginning of the period	11,825	1,581
Cash and cash equivalents at the end of the period	8,171	2,998
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Issuance of finance lease liability for finance lease right-of-use asset		$ 405

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Notable Labs, Ltd., previously known as Vascular Biogenics, Ltd., is an Israeli corporation (“Notable”). These consolidated financial statements include three wholly owned subsidiaries, Notable Labs, Inc. (“Notable US”), VBL, Inc. (“VBL”) and Notable Therapeutics, Inc. (“Therapeutics”) (together with Notable, the “Company”). All material intercompany transactions have been eliminated in consolidation. Notable US was incorporated as a Delaware corporation in 2014. Initially, Notable US developed its Predictive Precision Medicines Platform (“PPMP”) as a diagnostic tool for physicians for identifying which cancer treatment would be the most effective for an individual patient. Notable US then broadened its mission and applied its PPMP to streamline and accelerate the identification and validation of investigational compounds, working with multiple biotechnology and pharmaceutical companies under service-based agreements. In 2021, by entering into the Oncoheroes Agreement and the CicloMed Agreement, Notable US advanced from a purely diagnostic company to an integrated – diagnostic and therapeutic – platform therapeutics company designing and developing or co-developing predictive precision medicines. On October 16, 2023, pursuant to the Agreement and Plan of Merger, dated February 22, 2023 (the “Merger Agreement”), by and among Notable Labs, Ltd., Merger Sub, and Notable US, Merger Sub was merged with and into Notable US, with Notable US continuing after the merger as the surviving entity and a wholly owned subsidiary of Notable Labs, Ltd. (the “Merger”). At the effective time of the Merger, without any action on the part of any stockholder, each issued and outstanding share of pre-Merger Notable US common stock, par value $ 0.001 0.0629 0.35 1-for-35 reverse stock split In connection with the closing of the Merger, Notable changed its name to Notable Labs, Ltd. and Notable’s Ordinary Shares listed on The Nasdaq Capital Market, previously trading through the close of business on October 16, 2023 under the trading symbol “VBLT”, commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis, under the trading symbol “NTBL” on October 17, 2023. Liquidity and Going Concern Assessment The Company has incurred losses and negative cash flows from operations since its inception. As of March 31, 2024 and December 31, 2023, the Company had an accumulated deficit of approximately $ 86.1 82.3 8.2 The Company’s ability to fund its operations will require additional capital, and the Company intends to raise such capital through the issuance of additional debt or equity, including through licensing or collaboration agreements. These plans are intended to mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern; however, as the plans are not entirely within the Company’s control, management has determined it is not probable they will be effectively implemented. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern. The Company is continuing to develop its predictive medicine platform and treatments, which is the primary use of funds for the Company. Management expects to continue to incur additional substantial losses and negative cash flows from operations in the foreseeable future as a result of expanded research and development activities until regulatory approval is granted. Regulatory approval is not guaranteed and may never be obtained. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish these plans and secure sources of financing and ultimately attain profitable operations. However, if such financing is not approved, does not occur, or alternative financing is not available at adequate levels or on acceptable terms, or profitable operations are not attained, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of its development programs, enter into a collaboration or other similar arrangement with respect to commercialization rights to any of its product candidates, out license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above. Any of these actions could have a material adverse effect on the Company’s business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all. If the Company is unable to obtain adequate capital, it could be forced to cease operations. NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BASIS OF PREPARATION OF THE FIN

BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS	NOTE 2 – BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS The accompanying unaudited condensed consolidated financial statements of Notable have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should therefore be read in conjunction with the audited consolidated financial statements and notes included in Form 10-K, filed with the Securities and Exchange Commission on April 11, 2024. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for the fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year. Notable affected a 1-for-35 reverse stock split

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies and calculation methods applied in the preparation of the unaudited condensed consolidated interim financial statements as of March 31, 2024 are consistent with those applied in the preparation of the annual financial statements as of December 31, 2023 and for the year then ended. Revenue Recognition The Company performed certain diagnostics services on a limited basis as an outsourced provider during the three months ended March 31, 2024 and 2023, but such activities do not represent its major and ongoing central operations. The Company recognizes revenue from diagnostic services in the amount that reflects the consideration that it expects to be entitled as the Company performs its obligation under a contract with a customer by processing diagnostic tests on laboratory samples and making the test results available to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. The Company generally has a contract or a purchase order from a customer with the specified required terms, including the number of diagnostic samples to be performed. The Company has not received any advance payments for which there are any remaining performance obligations. Accordingly, no An allowance for doubtful accounts is established, as necessary, based on past experience and other factors which, in management’s judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company’s customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. At March 31, 2024 and December 31, 2023, an allowance for doubtful accounts was not considered necessary as all accounts receivable were deemed collectible. Cost of Services Cost of services represents costs directly related to the services performed. Cost of services is primarily comprised of cost of samples and labor. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP generally requires management to make certain estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, measurement of lease liabilities and right-of-use assets, impairment of long-lived assets, stock-based compensation, accrued research and development costs, SAFE notes and redeemable convertible preferred stock warrant liability in the accompanying condensed consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Segments The Company operates and manages its business as one reportable operating segment, which is the business of developing predictive precision medicines that treat various forms of cancer. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. All of the Company’s long-lived assets are maintained in, and all revenues and losses are attributable to, the United States of America. Recently Adopted Accounting Pronouncements As of March 31, 2024, there are no recently adopted accounting standards which the Company expects would have a material effect on the Company’s condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted As of March 31, 2024, there are no recently issued accounting standards not yet adopted which the Company expects would have a material effect on the Company’s condensed consolidated financial statements.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4 – FAIR VALUE MEASUREMENTS The following table sets forth the Company’s financial liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): SCHEDULE OF FAIR VALUE OF FINANCIAL LIABILITIES ON RECURRING BASIS Level 1 Level 2 Level 3 Total Fair As of March 31, 2024 Level 1 Level 2 Level 3 Total Fair Liabilities Warrant liability $ — $ — $ 152 $ 152 Level 1 Level 2 Level 3 Total Fair As of December 31, 2023 Level 1 Level 2 Level 3 Total Fair Liabilities Warrant liability $ — $ — $ 163 $ 163 There were no transfers between Levels 1, 2, or 3 during the three months ended March 31, 2024 and the year ended December 31, 2023. Additionally, there were no The value of the warrants was based on the estimated value of the warrant using the Black-Scholes-Merton model as of March 31, 2024. The following assumptions were used in determining the fair value of the warrants: SCHEDULE OF FAIR VALUE OF WARRANT Risk Free interest rate 4.2 % Expected life (years) 8.21 Expected volatility 164.7 % Annual dividend yield 0 % NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The following is a summary of the Company’s warrant liability activity for the three months ended March 31, 2024 (in thousands): SCHEDULE OF SAFE WARRANT LIABILITY Warrant liability Balance as of December 31, 2023 $ 163 Fair value of warrants at issuance Change in fair value (11 ) Balance as of March 31, 2024 $ 152 Warrant liability Balance as of December 31, 2022 $ 5,113 Change in fair value (1,096 ) Balance as of March 31, 2023 $ 4,017 The change in the fair value of the warrant liability resulted from a reduction in the value per warrant based on the fair market valuation of the warrants as of March 31, 2024. The reduction primarily for the three months ended March 31, 2024 related to the decrease in the price of the underlying shares and the increase for the three months ended March 31, 2023 related to the increase in the value of the underlying shares.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	NOTE 5 – BALANCE SHEET COMPONENTS Prepaid Expenses and Other Current Assets The following table presents the components of prepaid expenses and other current assets as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2024 December 31, 2023 Accounts receivable $ 183 $ 186 Employee retention credit 572 572 Prepaid expenses 2,754 2,857 Prepaid benefits 29 24 Prepaid clinical expenses 6 6 Total prepaid expenses and other current assets $ 3,544 $ 3,645 During fiscal years 2020 and 2021, the Company took advantage of the relief provisions provided by the U.S. government in response to COVID-19 under the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The CARES Act provides an employee retention credit (“Employee Retention Credit”), which is a refundable tax credit against certain employment taxes dependent on certain qualified wages paid to employees through fiscal year 2021. The Company qualifies for the tax credit under the CARES Act and continued to receive additional tax credits under the additional relief provisions for qualified wages through the end of 2021. The Company accounts for these labor related tax credits as a reduction to the expense that they are intended to compensate in the period in which the corresponding expense is incurred and there is reasonable assurance the Company will both receive the tax credits and comply with all conditions attached to the tax credits. As of March 31, 2024 and December 31, 2023, $ 0.6 0.7 Property and Equipment, Net The following table presents the components of property and equipment, net, as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2024 December 31, 2023 Computer equipment $ 194 $ 192 Laboratory equipment 1,999 1,999 Furniture and office equipment 29 29 Leasehold improvements 76 73 Property plant and equipment, gross 2,298 2,293 Less: accumulated depreciation (2,019 ) (1,977 ) Total property and equipment, net $ 279 $ 316 Depreciation expense was approximately $ 0.1 NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Investment in SAFE In October 2021, the Company entered into a simple agreement for future equity (“Oncoheroes SAFE”) agreement for $ 1.5 1.5 1.5 Accrued Expenses and Other Current Liabilities The following table presents the components of accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES March 31, 2024 December 31, 2023 Accrued expenses $ 102 107 Accrued employee expenses 8 78 Accrued bonuses 324 233 Total accrued expenses and other current liabilities $ 434 $ 418

ACCOUNTS PAYABLE - RELATED PART

ACCOUNTS PAYABLE - RELATED PARTIES	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE - RELATED PARTIES	NOTE 6 – ACCOUNTS PAYABLE - RELATED PARTIES As of March 31, 2024 and December 31, 2023, the Company owed related parties the following (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTIES March 31, 2024 December 31, 2023 Board Member $ 22 $ 42 For consulting services with the Board Member, the Company recorded general and administrative expenses of $ 60,450 43,403

CO-DEVELOPMENT AND LICENSE AGRE

CO-DEVELOPMENT AND LICENSE AGREEMENTS	3 Months Ended
	Mar. 31, 2024
Research and Development [Abstract]
CO-DEVELOPMENT AND LICENSE AGREEMENTS	NOTE 7 – CO-DEVELOPMENT AND LICENSE AGREEMENTS Oncoheroes Agreement In September 2021, the Company entered into an Exclusive License Agreement with Oncoheroes (the “Oncoheroes Agreement”) whereby the Company obtained worldwide exclusive development and commercialization rights in the small molecule volasertib for uses relating to certain types of cancer in adults. Under the terms of the Oncoheroes Agreement, Oncoheroes retains the right to develop and commercialize volasertib for cancers not licensed to the Company. NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Under the terms of the agreement, the Company is obligated to make additional clinical and regulatory milestone payments up to a total of $ 8.0 When a licensed product is submitted to NDA, the Company is required to pay $1 million, upon US NDA approval, the Company is required to pay $4 million and upon EU MAA Approval, the Company is required to pay $3 million. In the event the Company grants a sublicense of rights, the Company will need to pay Oncoheroes a high single digit percentage of any upfront payment obtained from such sublicenses No The Company also entered a SAFE agreement with Oncoheroes in October 2021 for $ 1.5 CicloMed Agreement In July 2021, the Company entered into a Co-Development and Profit-Sharing Agreement with CicloMed LLC (“CicloMed”) (the “CicloMed Agreement”) regarding use of the Company’s precision oncology diagnostic test in the research and development of CicloMed’s CicloProx product for the treatment of acute myeloid leukemia. Under the terms of the co-development agreement, CicloMed holds the primary responsibility for executing clinical trial operations while the Company is primarily focused on optimizing the Company’s predictive precision medicine platform. Both parties will equally share the costs associated with the on-going clinical trial incurred after the effective date. In the event a CicloProx product is commercially developed and sold, the parties will share in the net proceeds. The Company recorded $ 0 0.1

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES As of January 1, 2023, the Company had no no no Tax years from 2020 through 2023 remain subject to examination by major tax jurisdictions There is no

LEASES

LEASES	3 Months Ended
	Mar. 31, 2024
Leases
LEASES	NOTE 9 - LEASES The following table summarizes total lease expense during the three months ended March 31, 2024 and 2023 (in thousands): SCHEDULE OF LEASES EXPENSES March 31, 2024 March 31, 2023 Amortization of ROU assets - finance lease $ 20 $ 7 Interest on lease liabilities - finance lease $ 3 $ 1 Cash paid for financing lease liabilities $ 22 $ - Cash paid for operating lease liabilities $ 132 $ 187 Operating lease expense $ 120 $ 185 Variable lease expense $ 4 $ 22 Short-term lease expense $ 1 $ - NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of March 31, 2024 (in thousands): SCHEDULE OF MATURITIES OF LEASE LIABILITIES AND THE RECONCILIATION OF LEASE LIABILITIES Lease Obligation Finance Lease Facilities Lease 2024 $ 66 $ 404 2025 87 552 2026 87 569 2027 87 239 2028 and thereafter 15 - Total future undiscounted lease payments 342 1,764 Less: imputed interest (20 ) (163 ) Total lease liabilities $ 322 $ 1,601

EQUITY INCENTIVE PLANS AND STOC

EQUITY INCENTIVE PLANS AND STOCK BASED COMPENSATION EXPENSE	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
EQUITY INCENTIVE PLANS AND STOCK BASED COMPENSATION EXPENSE	NOTE 10 – EQUITY INCENTIVE PLANS AND STOCK BASED COMPENSATION EXPENSE 2000 Plan In February 2000, Notable’s Board of Directors approved an option plan (the “2000 Plan”) as amended through 2008. Under the 2000 Plan, the Company reserved up to 40,674 0.01 Each option provides the holder the right to exercise such option and acquire one Ordinary Share per option. Any option granted under the Plan that is not exercised within ten years from the date upon which it becomes exercisable, will expire. 2011 Plan In April 2011, Notable’s board of directors approved a new option plan (the “2011 Plan”). Under the 2011 Plan, the Company reserved up to 21,913 4,556 Any option which was granted under the 2011 Plan and was not exercised within twenty years from the date when it becomes exercisable, will expire. 2014 Equity Incentive Plan In September 2014, Notable’s shareholders approved the adoption of the Employee Share Ownership and Option Plan (2014) (“2014 Plan”) effective as of the closing of the public offering. Under the 2014 Plan, Notable reserved up to 26,514 800 Any option which was granted under the 2014 Plan and was not exercised within twenty years from the date when it becomes exercisable, will expire. 2015 Equity Incentive Plan Notable adopted the 2015 Equity Incentive Plan (the “2015 Plan”) in August 2015, which provides for the granting of ISO, NSO, and restricted shares to employees, directors, and consultants. The 2015 Plan authorized a total of 37,199 160,253 141,094 31,450 66,975 Options under the 2015 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board provided that the exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The 2015 Plan requires that options be exercised no later than 10 years after the grant. Options granted to employees generally vest ratably on a monthly basis over four years, subject to cliff vesting restrictions and continuing service. 2024 Employee Share Ownership and Option Plan Notable adopted the 2024 Employee Share Ownership and Option Plan (the “2024 Plan”) in March 2024, which provides for the granting of ISO, NSO, restricted shares and restricted units to employees, directors, and consultants. The 2024 Plan authorized a total of 4 (i) on an annual basis on January 1 of each year (unless resolved otherwise by the Board of Directors), such that the number of shares issuable under the Plan shall equal 35% of the Company’s issued and outstanding share capital on a fully diluted basis; and (ii) in the event that any Ordinary Shares would have otherwise returned to the Company’s employee share ownership and option plans of 2000, 2011 and 2014, such Ordinary Shares shall be added to this Plan 4 NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Options under the 2024 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board provided that the exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The 2024 Plan requires that options be exercised no later than 10 years after the grant. Options granted to employees generally vest ratably on a monthly basis over four years, subject to cliff vesting restrictions and continuing service. The following summarizes stock option activity under all of the Plans: SCHEDULE OF STOCK OPTIONS Options Outstanding Total Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of December 31, 2023 284,437 $ 49.67 4.0 $ - Granted 55,299 $ 1.28 - - Cancelled (141,289 ) $ 75.45 - - Outstanding as of March 31, 2024 198,447 $ 17.83 7.9 $ 27 Exercisable as of March 31, 2024 135,375 $ 24.28 7.0 $ - Vested and expected to vest as of March 31, 2024 198,447 $ 17.83 7.9 $ 27 No no Stock-Based Compensation Expense During the three months ended March 31, 2024 and 2023, the Company issued in aggregate 55,299 0 1.28 ● Risk-free interest rate ● Expected volatility ● Expected term ● Expected dividend rate NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The fair value of stock options granted during the three months ended March 31, 2024 was estimated using the following weighted-average assumptions: SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTION 2024 Expected term (in years) 10 Risk-free interest rate 4.2 % Expected dividend rate - % Expected volatility 170.7 % The following table summarizes the components of stock-based compensation expense relating to options recognized in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands): SCHEDULE OF SHARE BASED COMPENSATION Three months ended March 31, 2024 2023 Research and development $ 99 $ 26 General and administrative 33 90 Total $ 132 $ 116 As of March 31, 2024, the total stock-based compensation expense related to stock awards not yet recognized was $ 0.5 0.7

NET LOSS PER SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NOTE 11 – NET LOSS PER SHARE The following table sets forth the computation of the basic and diluted net loss per share (in thousands except share and per share data): SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE 2024 2023 For the Three Months Ended March 31, 2024 2023 Numerator: Net loss $ (3,766 ) $ (6,272 ) Denominator: Weighted-average ordinary shares outstanding used to compute net loss per share, basic and diluted 9,018,261 970,192 Net loss per share, basic and diluted: $ (0.42 ) $ (6.46 ) The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share is the same.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS The Company received Employee Retention Credit refund checks that were deposited in April 2024, in the total amount of $ 251,220 On May 8, 2024, the Company issued options to purchase 390,000 70,000 350,000 30,000 400,000 In addition, the Company issued 40,247 65,247

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company performed certain diagnostics services on a limited basis as an outsourced provider during the three months ended March 31, 2024 and 2023, but such activities do not represent its major and ongoing central operations. The Company recognizes revenue from diagnostic services in the amount that reflects the consideration that it expects to be entitled as the Company performs its obligation under a contract with a customer by processing diagnostic tests on laboratory samples and making the test results available to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. The Company generally has a contract or a purchase order from a customer with the specified required terms, including the number of diagnostic samples to be performed. The Company has not received any advance payments for which there are any remaining performance obligations. Accordingly, no An allowance for doubtful accounts is established, as necessary, based on past experience and other factors which, in management’s judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company’s customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. At March 31, 2024 and December 31, 2023, an allowance for doubtful accounts was not considered necessary as all accounts receivable were deemed collectible.
Cost of Services	Cost of Services Cost of services represents costs directly related to the services performed. Cost of services is primarily comprised of cost of samples and labor.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP generally requires management to make certain estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, measurement of lease liabilities and right-of-use assets, impairment of long-lived assets, stock-based compensation, accrued research and development costs, SAFE notes and redeemable convertible preferred stock warrant liability in the accompanying condensed consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. NOTABLE LABS, LTD. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Segments	Segments The Company operates and manages its business as one reportable operating segment, which is the business of developing predictive precision medicines that treat various forms of cancer. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. All of the Company’s long-lived assets are maintained in, and all revenues and losses are attributable to, the United States of America.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements As of March 31, 2024, there are no recently adopted accounting standards which the Company expects would have a material effect on the Company’s condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted As of March 31, 2024, there are no recently issued accounting standards not yet adopted which the Company expects would have a material effect on the Company’s condensed consolidated financial statements.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE OF FINANCIAL LIABILITIES ON RECURRING BASIS	The following table sets forth the Company’s financial liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): SCHEDULE OF FAIR VALUE OF FINANCIAL LIABILITIES ON RECURRING BASIS Level 1 Level 2 Level 3 Total Fair As of March 31, 2024 Level 1 Level 2 Level 3 Total Fair Liabilities Warrant liability $ — $ — $ 152 $ 152 Level 1 Level 2 Level 3 Total Fair As of December 31, 2023 Level 1 Level 2 Level 3 Total Fair Liabilities Warrant liability $ — $ — $ 163 $ 163
SCHEDULE OF FAIR VALUE OF WARRANT	The value of the warrants was based on the estimated value of the warrant using the Black-Scholes-Merton model as of March 31, 2024. The following assumptions were used in determining the fair value of the warrants: SCHEDULE OF FAIR VALUE OF WARRANT Risk Free interest rate 4.2 % Expected life (years) 8.21 Expected volatility 164.7 % Annual dividend yield 0 %
SCHEDULE OF SAFE WARRANT LIABILITY	The following is a summary of the Company’s warrant liability activity for the three months ended March 31, 2024 (in thousands): SCHEDULE OF SAFE WARRANT LIABILITY Warrant liability Balance as of December 31, 2023 $ 163 Fair value of warrants at issuance Change in fair value (11 ) Balance as of March 31, 2024 $ 152 Warrant liability Balance as of December 31, 2022 $ 5,113 Change in fair value (1,096 ) Balance as of March 31, 2023 $ 4,017

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	The following table presents the components of prepaid expenses and other current assets as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2024 December 31, 2023 Accounts receivable $ 183 $ 186 Employee retention credit 572 572 Prepaid expenses 2,754 2,857 Prepaid benefits 29 24 Prepaid clinical expenses 6 6 Total prepaid expenses and other current assets $ 3,544 $ 3,645
SCHEDULE OF PROPERTY AND EQUIPMENT	The following table presents the components of property and equipment, net, as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2024 December 31, 2023 Computer equipment $ 194 $ 192 Laboratory equipment 1,999 1,999 Furniture and office equipment 29 29 Leasehold improvements 76 73 Property plant and equipment, gross 2,298 2,293 Less: accumulated depreciation (2,019 ) (1,977 ) Total property and equipment, net $ 279 $ 316
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	The following table presents the components of accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023 (in thousands): SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES March 31, 2024 December 31, 2023 Accrued expenses $ 102 107 Accrued employee expenses 8 78 Accrued bonuses 324 233 Total accrued expenses and other current liabilities $ 434 $ 418

ACCOUNTS PAYABLE - RELATED PA_2

ACCOUNTS PAYABLE - RELATED PARTIES (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTIES	As of March 31, 2024 and December 31, 2023, the Company owed related parties the following (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTIES March 31, 2024 December 31, 2023 Board Member $ 22 $ 42

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2024
Leases
SCHEDULE OF LEASES EXPENSES	The following table summarizes total lease expense during the three months ended March 31, 2024 and 2023 (in thousands): SCHEDULE OF LEASES EXPENSES March 31, 2024 March 31, 2023 Amortization of ROU assets - finance lease $ 20 $ 7 Interest on lease liabilities - finance lease $ 3 $ 1 Cash paid for financing lease liabilities $ 22 $ - Cash paid for operating lease liabilities $ 132 $ 187 Operating lease expense $ 120 $ 185 Variable lease expense $ 4 $ 22 Short-term lease expense $ 1 $ -
SCHEDULE OF MATURITIES OF LEASE LIABILITIES AND THE RECONCILIATION OF LEASE LIABILITIES	The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of March 31, 2024 (in thousands): SCHEDULE OF MATURITIES OF LEASE LIABILITIES AND THE RECONCILIATION OF LEASE LIABILITIES Lease Obligation Finance Lease Facilities Lease 2024 $ 66 $ 404 2025 87 552 2026 87 569 2027 87 239 2028 and thereafter 15 - Total future undiscounted lease payments 342 1,764 Less: imputed interest (20 ) (163 ) Total lease liabilities $ 322 $ 1,601

EQUITY INCENTIVE PLANS AND ST_2

EQUITY INCENTIVE PLANS AND STOCK BASED COMPENSATION EXPENSE (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTIONS	The following summarizes stock option activity under all of the Plans: SCHEDULE OF STOCK OPTIONS Options Outstanding Total Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of December 31, 2023 284,437 $ 49.67 4.0 $ - Granted 55,299 $ 1.28 - - Cancelled (141,289 ) $ 75.45 - - Outstanding as of March 31, 2024 198,447 $ 17.83 7.9 $ 27 Exercisable as of March 31, 2024 135,375 $ 24.28 7.0 $ - Vested and expected to vest as of March 31, 2024 198,447 $ 17.83 7.9 $ 27
SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTION	The fair value of stock options granted during the three months ended March 31, 2024 was estimated using the following weighted-average assumptions: SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTION 2024 Expected term (in years) 10 Risk-free interest rate 4.2 % Expected dividend rate - % Expected volatility 170.7 %
SCHEDULE OF SHARE BASED COMPENSATION	The following table summarizes the components of stock-based compensation expense relating to options recognized in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands): SCHEDULE OF SHARE BASED COMPENSATION Three months ended March 31, 2024 2023 Research and development $ 99 $ 26 General and administrative 33 90 Total $ 132 $ 116

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE	The following table sets forth the computation of the basic and diluted net loss per share (in thousands except share and per share data): SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE 2024 2023 For the Three Months Ended March 31, 2024 2023 Numerator: Net loss $ (3,766 ) $ (6,272 ) Denominator: Weighted-average ordinary shares outstanding used to compute net loss per share, basic and diluted 9,018,261 970,192 Net loss per share, basic and diluted: $ (0.42 ) $ (6.46 )

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) $ / shares in Units, $ in Thousands		3 Months Ended
	Oct. 16, 2023 $ / shares	Mar. 31, 2024 USD ($)	Mar. 31, 2024 ₪ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ₪ / shares	Oct. 16, 2023 ₪ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value | ₪ / shares			₪ 0.35		₪ 0.35
Reverse stock split		1-for-35 reverse stock split
Accumulated deficit | $		$ 86,074		$ 82,308
Cash | $		$ 8,171		$ 11,825
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value | $ / shares	$ 0.001
Converted shares | $ / shares	$ 0.0629
Preferred stock, par value | ₪ / shares						₪ 0.35
Reverse stock split	1-for-35 reverse stock split

BASIS OF PREPARATION OF THE F_2

BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS (Details Narrative)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1-for-35 reverse stock split

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Deferred revenue	$ 0	$ 0

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL LIABILITIES ON RECURRING BASIS (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 152	$ 163
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 152	$ 163

SCHEDULE OF FAIR VALUE OF WARRA

SCHEDULE OF FAIR VALUE OF WARRANT (Details)	Mar. 31, 2024
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Annual dividend yield	4.2
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (years)	8 years 2 months 15 days
Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Annual dividend yield	164.7
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Annual dividend yield	0

SCHEDULE OF SAFE WARRANT LIABIL

SCHEDULE OF SAFE WARRANT LIABILITY (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Balance as of December 31, 2022	$ 163
Balance as of March 31, 2023	152
Warrant Liability [Member]
Balance as of December 31, 2022	163	$ 5,113
Change in fair value	(11)	(1,096)
Balance as of March 31, 2023	$ 152	$ 4,017

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Cash equivalents	$ 0	$ 0

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 183	$ 186
Employee retention credit	572	572
Prepaid expenses	2,754	2,857
Prepaid benefits	29	24
Prepaid clinical expenses	6	6
Total prepaid expenses and other current assets	$ 3,544	$ 3,645

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 2,298	$ 2,293
Less: accumulated depreciation	(2,019)	(1,977)
Total property and equipment, net	279	316
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	194	192
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	1,999	1,999
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	29	29
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 76	$ 73

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued expenses	$ 102	$ 107
Accrued employee expenses	8	78
Accrued bonuses	324	233
Total accrued expenses and other current liabilities	$ 434	$ 418

BALANCE SHEET COMPONENTS (Detai

BALANCE SHEET COMPONENTS (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Oct. 31, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid and other current assets		$ 600		$ 600
Proceeds from accounts receivable			$ 700
Depreciation expense		63	$ 68
Investment in SAFE	$ 1,500
Issuance initial public offering	1,500
Oncoheroes Safe Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment in SAFE	$ 1,500
Investment		$ 1,500		$ 1,500

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTIES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Total	$ 22	$ 42
Board [Member]
Total	$ 22	$ 42

ACCOUNTS PAYABLE - RELATED PA_3

ACCOUNTS PAYABLE - RELATED PARTIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Board [Member]
General and administrative expenses	$ 60,450	$ 43,403

CO-DEVELOPMENT AND LICENSE AG_2

CO-DEVELOPMENT AND LICENSE AGREEMENTS (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2024	Mar. 31, 2023	Oct. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment in SAFE				$ 1,500
Research and development expense		$ 1,550	$ 1,596
Oncoheroes Safe Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments
Frequency of payments	When a licensed product is submitted to NDA, the Company is required to pay $1 million, upon US NDA approval, the Company is required to pay $4 million and upon EU MAA Approval, the Company is required to pay $3 million. In the event the Company grants a sublicense of rights, the Company will need to pay Oncoheroes a high single digit percentage of any upfront payment obtained from such sublicenses
Investment in SAFE				$ 1,500
Oncoheroes Safe Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	$ 8,000
CicloMed Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense		$ 0	$ 100

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 01, 2023
Income Tax Disclosure [Abstract]
unrecognized tax benefits			$ 0
Change in unrecognized tax benefits	$ 0
Accrual for uncertain tax positions	$ 0
Subject to examination	Tax years from 2020 through 2023 remain subject to examination by major tax jurisdictions
Income tax benefit	$ 0	$ 0

SCHEDULE OF LEASES EXPENSES (De

SCHEDULE OF LEASES EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases
Amortization of ROU assets - finance lease	$ 20	$ 7
Interest on lease liabilities - finance lease	3	1
Cash paid for financing lease liabilities	22
Cash paid for operating lease liabilities	132	187
Operating lease expense	120	185
Variable lease expense	4	22
Short-term lease expense	$ 1

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES AND THE RECONCILIATION OF LEASE LIABILITIES (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Leases
Finance Lease Obligation, 2024	$ 66
Facilities Lease Obligation, 2024	404
Finance Lease Obligation, 2025	87
Facilities Lease Obligation, 2025	552
Finance Lease Obligation, 2026	87
Facilities Lease Obligation, 2026	569
Finance Lease Obligation, 2027	87
Facilities Lease Obligation, 2027	239
Finance Lease Obligation, 2028 and thereafter	15
Facilities Lease Obligation, 2028 and thereafter
Finance Lease Obligation, Total future undiscounted lease payments	342
Facilities Lease Obligation, Total future undiscounted lease payments	1,764
Finance Lease Obligation, imputed interest	(20)
Facilities Lease Obligation, imputed interest	(163)
Total Finance Lease Obligation	322
Total Facilities Lease Obligation	$ 1,601

SCHEDULE OF STOCK OPTIONS (Deta

SCHEDULE OF STOCK OPTIONS (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Total Options Outstanding, Outstanding beginning balance | shares	284,437
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 49.67
Weighted Average Remaining Contractual Life (in years), Outstanding	4 years
Aggregate Intrinsic Value, Outstanding | $
Total Options Outstanding, Granted | shares	55,299
Weighted Average Exercise Price, Granted | $ / shares	$ 1.28
Total Options Outstanding, Cancelled | shares	(141,289)
Weighted Average Exercise Price, Cancelled | $ / shares	$ 75.45
Total Options Outstanding, Outstanding ending balance | shares	198,447
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 17.83
Weighted Average Remaining Contractual Life (in years), Outstanding	7 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding | $	$ 27
Total Options Outstanding, Exercisable | shares	135,375
Weighted Average Exercise Price, Exercisable | $ / shares	$ 24.28
Weighted Average Remaining Contractual Life (in years), Exercisable	7 years
Aggregate Intrinsic Value, Exercisable | $
Total Options Outstanding, Vested and expected to vest | shares	198,447
Weighted Average Exercise Price, Vested and expected to vest | $ / shares	$ 17.83
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest	7 years 10 months 24 days
Aggregate Intrinsic Value, Vested and expected to vest | $	$ 27

SCHEDULE OF STOCK OPTIONS GRANT

SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTION (Details)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Expected term (in years)	10 years
Risk-free interest rate	4.20%
Expected dividend rate
Expected volatility	170.70%

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	$ 132	$ 116
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	99	26
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	$ 33	$ 90

EQUITY INCENTIVE PLANS AND ST_3

EQUITY INCENTIVE PLANS AND STOCK BASED COMPENSATION EXPENSE (Details Narrative) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended
	Sep. 30, 2014 shares	Apr. 30, 2011 shares	Feb. 28, 2000 ₪ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2024 ₪ / shares	Dec. 31, 2023 ₪ / shares	Dec. 31, 2022 shares	Dec. 31, 2019 shares	Dec. 31, 2017 shares	Aug. 31, 2015 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares, par value | ₪ / shares						₪ 0.35	₪ 0.35
Intrinsic value of stock options exercised | $				$ 0	$ 0
Restricted stock activity, outstanding
Options granted				55,299
Options grant date fair value per share | $ / shares				$ 1.28
Stock-based compensation expense related to stock awards not yet recognized | $				$ 500
Weighted-average remaining period				8 months 12 days
2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares reserved for future issuance	26,514
Share-based compensation arrangement by share-based payment award, description	Any option which was granted under the 2014 Plan and was not exercised within twenty years from the date when it becomes exercisable, will expire.
Share based compensation, shares unallocated pool reserved	800
2015 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares reserved for future issuance				66,975				31,450	141,094	160,253	37,199
Share-based compensation arrangement by share-based payment award, description				Options under the 2015 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board provided that the exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The 2015 Plan requires that options be exercised no later than 10 years after the grant. Options granted to employees generally vest ratably on a monthly basis over four years, subject to cliff vesting restrictions and continuing service.
2024 Employee Share Ownership and Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares reserved for future issuance				4,000,000
Share-based compensation arrangement by share-based payment award, description				Options under the 2024 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board provided that the exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The 2024 Plan requires that options be exercised no later than 10 years after the grant. Options granted to employees generally vest ratably on a monthly basis over four years, subject to cliff vesting restrictions and continuing service.
Share-based compensation arrangement by share-based payment award, ordinary shares description				(i) on an annual basis on January 1 of each year (unless resolved otherwise by the Board of Directors), such that the number of shares issuable under the Plan shall equal 35% of the Company’s issued and outstanding share capital on a fully diluted basis; and (ii) in the event that any Ordinary Shares would have otherwise returned to the Company’s employee share ownership and option plans of 2000, 2011 and 2014, such Ordinary Shares shall be added to this Plan
Board of Directors [Member] | 2000 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares reserved for future issuance			40,674
Ordinary shares, par value | ₪ / shares			₪ 0.01
Share-based compensation arrangement by share-based payment award, description			Each option provides the holder the right to exercise such option and acquire one Ordinary Share per option. Any option granted under the Plan that is not exercised within ten years from the date upon which it becomes exercisable, will expire.
Board of Directors [Member] | 2011 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Ordinary shares reserved for future issuance		21,913
Share-based compensation arrangement by share-based payment award, description		Any option which was granted under the 2011 Plan and was not exercised within twenty years from the date when it becomes exercisable, will expire.
Share based compensation, shares unallocated pool reserved		4,556
Six Board Members [Member] | 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted				55,299	0

SCHEDULE OF BASIC AND DILUTED L

SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (3,766)	$ (6,272)
Weighted-average ordinary shares outstanding used to compute net loss per share, basic	9,018,261	970,192
Weighted-average ordinary shares outstanding used to compute net loss per share, diluted	9,018,261	970,192
Net loss per share, basic	$ (0.42)	$ (6.46)
Net loss per share, diluted	$ (0.42)	$ (6.46)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)		1 Months Ended
	May 08, 2024	Apr. 30, 2024
Subsequent Event [Line Items]
Received employee retention credit refund from deposit		$ 251,220
Employees [Member]
Subsequent Event [Line Items]
Number of option to purchase share of ordinary shares	390,000
Consultants [Member]
Subsequent Event [Line Items]
Number of option to purchase share of ordinary shares	70,000
Number of restricted ordinary shares issued	30,000
Officer [Member]
Subsequent Event [Line Items]
Number of option to purchase share of ordinary shares	350,000
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	400,000
Board Member One [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	40,247
Board Member Two [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	40,247
Board Member Three [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	40,247
Board Member Four [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	40,247
Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Number of restricted ordinary shares issued	65,247